FDA Approval Alert: The Need-to-Know | Amivantamab/Lazertinib in Advanced EGFR+ NSCLC

In August 2024, the FDA approved amivantamab-vmjw in combination with lazertinib as frontline therapy for patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Findings from the MARIPOSA trial support the FDA approval of frontline amivantamab/lazertinib in advanced or metastatic EGFR-mutant NSCLC.
FDA Approves Amivantamab Combo in Advanced EGFR-mutated NSCLC
Article
Aug 20, 2024 12:33 PM
Findings from the MARIPOSA trial support the FDA approval of frontline amivantamab/lazertinib in advanced or metastatic EGFR-mutant NSCLC.